Company news
Dicot Pharma Ab (OMXSTO:DICOT) news
Dicot Pharma Ab news releases on 6ix. Latest, Aug 19, 2026: Dicot Pharma: three abstracts on LIB-01 selected for presentation at leading sexual medicine…
Press releases & updates
Dicot Pharma: three abstracts on LIB-01 selected for presentation at leading sexual medicine conference
August 19, 2026
Dicot Pharma Recruits Cecilia Driving As CFO
July 1, 2026
Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S.
June 25, 2026
Dicot Pharma announces last day of trading in BTU and first day of trading in warrants of series TO 7
June 24, 2026
Dicot Pharma Announces Outcome In Oversubscribed Rights Issue
June 9, 2026
Dicot Pharma presents at Aktiespararnas’ event Aktiedagarna on June 9
June 5, 2026
Dicot Pharma announces preliminary outcome in oversubscribed rights issue
June 4, 2026
Dicot Pharma announces the final subscription date for units in the ongoing rights issue
May 29, 2026
DICOT: Over 80% of the rights issue is secured, ensuring funding for the planned phase 2b study
May 27, 2026
Dicot Pharma Submits IND Application To FDA
May 25, 2026
Dicot Pharma Invites to a live company presentation and Q&A session in Swedish on May 27
May 22, 2026
The subscription period in Dicot Pharma’s rights issue commences today
May 21, 2026
Dicot Pharma completes tablet manufacturing ahead of phase 2b clinical study
May 20, 2026
Dicot Pharma publishes prospectus in connection with the forthcoming rights issue
May 19, 2026
Dicot Pharma Resolves On Rights Issue Of About SEK 210 Mln
May 11, 2026
Dicot Pharma has resolved on an 80% guaranteed rights issue of approximately SEK 210 million
May 8, 2026
Report from the Annual General Meeting of Dicot Pharma
May 6, 2026
Dicot Pharma B - Q1 Net Sales Amount To Sek 0.0 Million
April 30, 2026
Dicot To Carry Out Rights Issue Of SEK 210 Million
April 28, 2026
Pharma publishes its Annual Report for 2025
April 9, 2026
NOTICE OF ANNUAL GENERAL MEETING IN DICOT PHARMA AB
April 2, 2026
Dicot Pharma initiates tablet manufacturing ahead of phase 2b clinical study
March 12, 2026
DICOT: LIB-01 demonstrated long-lasting efficacy in phase 2a, supporting further clinical development
February 18, 2026
Dicot Pharma to present at the Oppenheimer 36th Healthcare Life Sciences Conference
February 2, 2026
Dicot Pharma Signs Agreement With CRO Ahead Of Phase 2B Study With Lib-01
December 18, 2025
Dicot Pharma Submits Patent Application For LIB-01
November 21, 2025
Dicot Pharma Q3 Loss After Financial Items SEK 16.1 Mln
October 23, 2025
DICOT: Phase 2a study enrollment completed; strong cash position supports next development steps
August 12, 2025
DICOT: Strong warrant uptake and robust cash position support ongoing LIB-01 clinical progress
April 29, 2025
Dicot Pharma's TO 6 subscribed at 96% and provides the company SEK 43.8 million
April 2, 2025
DICOT: LIB-01 advanced in clinical trials, secured funding, and expanded IP, positioning for growth
February 13, 2025
Dicot Pharma granted new patent in the USA
November 26, 2024
Dicot Pharma: Dicot Pharma listed on Nasdaq First North
November 6, 2024
DICOT: LIB-01 phase 2a trial fully funded after oversubscribed rights issue; Nasdaq listing approved
October 31, 2024
DICOT: Phase 2a for LIB-01 is fully funded after a 65%-secured SEK 122.6M rights issue
August 9, 2024